This campaign has now closed
Vigabatrin is widely recognised as a very effective antiepileptic drug but can cause serious visual field defects in some patients. This project will aim to diminish these risks for all epilepsy sufferers.
Categories
Beneficiaries
Campaign overview
Impact & reporting
Situation
A 2 year research study led by DR Sisodiya at the UCL Institute of Neurology in London investigating whether a visual side effect of an important antiepileptic drug used in TSC can be attributed to a particular genetic mutation/s, and a way round the current difficulty in measuring and monitoring visual field in certain patient groups.